CPI-1189
CAS: 183619-38-7
Rif. 3D-IHA61938
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione | ||
| 100mg | Fuori produzione | ||
| 250mg | Fuori produzione |
Informazioni sul prodotto
- Ren-1189
- Cpi-1189
- 4-(acetylamino)-N-tert-butylbenzamide
CPI-1189 is a novel, potent and selective inhibitor of TNF-α. In vitro studies have shown that CPI-1189 has excellent activity against HIV infection and disease activity in animal models. It also has neuroprotective effects by inhibiting the release of inflammatory mediators from activated microglia cells. Clinical trials are being conducted to assess the safety and efficacy of CPI-1189 for treatment of inflammatory bowel disease, bowel disease and other conditions.
CPI-1189 is an orally active compound with a high bioavailability. It binds tightly to human TNF-α, preventing it from binding to its receptor on the surface of target cells which leads to inhibition of TNF-α mediated signalling pathways including NFκB activation, cytokine production and cell proliferation. This agent also inhibits dextran sulfate sodium (DSS) induced colitis in mice.
